Topiramate: Effects on serum lipids and lipoproteins levels in children

European Journal of Neurology

Volumn 14, Issue 12, 2007, Pages 1334-1337

  Franzoni, E ^a,b   Verrotti, A ^c   Sarajlija, J ^b   Garone, C ^b   Matricardi, S ^c   Salerno, G G ^b   Monti, M ^b   Chiarelli, F ^c  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF CHIETI   (Italy)

Author keywords

Children; Epilepsy; Serum lipids and lipoproteins; Topiramate

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TOPIRAMATE; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; ARTICLE; BODY MASS; CHILD; CONTROLLED STUDY; EPILEPSY; GROWTH CURVE; HUMAN; HYPERLIPIDEMIA; INFANT; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MONOTHERAPY; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGE FACTORS; ANTICONVULSANTS; APOLIPOPROTEINS; CHILD; CHILD, PRESCHOOL; CHOLESTEROL; DYSLIPIDEMIAS; EPILEPSY; FEMALE; FRUCTOSE; HUMANS; INFANT; LIPIDS; LIPOPROTEIN(A); LIPOPROTEINS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MALE; PROSPECTIVE STUDIES; TIME; TREATMENT OUTCOME;

EID: 36248933046     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2007.01973.x     Document Type: Article

References (23)

1. Robins DK, Wedlund PJ, Elsberg S. Interaction of valproic acid and some analogues with microsomal epoxide hydrolase. Biochemical Pharmacology 1992 43: 775 783.
2. Heldenberg D, Harel S, Holtzman M, Levtow O, Tamir I. The effect of chronic anticonvulsant therapy on serum lipid levels in children with epilepsy. Neurology 1983 33: 510 513.
3. Eiris J, Novo-Rodriguez MI, Del Rio M, Meseguer P, Del Rio MC, Castro-Gago M. The effects on lipid and apolipoprotein serum levels of long-term carbamazepine, valproic acid and phenobarbital therapy in children with epilepsy. Epilepsy Research 2000 41: 1 7.
4. Mahmoudian T, Iranpour R, Messri N. Serum lipid levels during carbamazepine therapy in epileptic children. Epilepsy and Behavior 2005 6: 257 259.
5. Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics and mechanism of action. Epilepsia 2000 41 (s1 S3 S9.
6. Crawford P. An audit of topiramate use in a general neurology clinic. Seizure 1998 7: 207 211.
7. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989 30: 389 399.
8. Verrotti A, Basciani F, Domizio S, Sabatino G, Morgese G, Chiarelli F. Serum lipids and lipoproteins in patients treated with antiepileptic drugs. Pediatric Neurology 1998 19: 364 367.
9. Verrotti A, Domizio S, Angelozzi B, Sabatino G, Morgese G, Chiarelli F. Changes in serum lipids and lipoproteins in epileptic children treated with anticonvulsivants. Journal of Pediatrics and Child Health 1997 33: 242 245.
10. American Academy of Pediatrics, Committee on Nutrition. Statement on cholesterol. Pediatrics 1992 90: 469 473.
11. Benedetti MS, Ruty B, Baltes E. Induction of endogenous pathways by antiepileptics and clinical implications. Fundamental and Clinical Pharmacology 2005 19: 511 529.
12. Franzoni E, Govoni M, D'Addato S, et al. Total cholesterol, high-density lipoprotein cholesterol and triglycerides in children receiving antiepileptic drugs. Epilepsia 1992 33: 932 935.
13. Isojarvi JI, Pakarinen AJ, Myllyla VV. Serum lipid levels during carbamazepine medication. A prospective study. Archives of Neurology 1993 50: 590 593.
14. Isojarvi JI, Pakarinen AJ, Rautio A, Pelkonen O, Myllyla VV. Liver enzyme induction and serum lipid levels after replacement of carbamazepine with oxcarbazepine. Epilepsia 1994 35: 1217 1220.
15. Benedetti MS. Enzyme induction and inhibition by new antiepileptic drugs: a review of human studies. Fundamental and Clinical Pharmacology 2000 14: 301 319.
16. Calandre EP, Rodriguez-Lopez C, Blasquez A, Cano D. Serum lipids, lipoproteins and apolipoproteins A and B in epileptic patients treated with valproic acid, carbamazepine or phenobarbital. Acta Neurologica Scandinavica 1991 83: 250 253.
17. Zeitlhofer J, Doppelbauer A, Tribl G, Leitha T, Deecke L. Changes in serum lipid pattern during long-term anticonvulsive treatment. Clinical Investigation 1993 71: 574 578.
18. Franzoni E, Marchiani V, Cecconi I, et al. Preliminary report on effects of oxcarbazepine-treatment on serum lipid levels in children. European Journal of Neurology 2006 13: 1389 1391.
19. Ben-Menachem E, Axelsen M, Johanson EH, Stagge A, Smith U. Predictors of weight loss in adults with topiramate-treated epilepsy. Obesity Research 2003 11: 556 562.
20. Astrup A, Caterson I, Zelissen P, et al. Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects. Obesity Research 2004 12: 1658 1669.
21. Reiter E, Feucht M, Hauser E, Freilinger M, Seidl R. Changes in body mass index during longterm topiramate therapy in paediatric epilepsy patients: a retrospective analysis. Seizure 2004 13: 491 493.
22. Garnett WR. Clinical pharmacology of topiramate: a review. Epilepsia 2000 41 (s1 61 65.
23. Olofsson SO, Boren J. Apolipoprotein B: a clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis. Journal of Internal Medicine 2005 258: 395 410.